Trial Profile
Insulin Degludec for the Management of Patient With Recurrent Diabetic Ketoacidosis
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Insulin degludec (Primary) ; Insulin detemir; Insulin glargine
- Indications Diabetic ketoacidosis
- Focus Therapeutic Use
- 13 May 2021 Status changed from recruiting to discontinued.
- 05 Apr 2021 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last Verified April 2019 by Hennepin Healthcare Research Institute)
- 15 Apr 2019 Planned End Date changed from 1 Jan 2019 to 31 Dec 2019.